Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 29, 2025
Product Development
Bispecifics for I&I: Bypassing combination complexity
At least 30 companies have bispecific antibodies in development for autoimmune and inflammatory diseases
BioCentury | Feb 21, 2025
Emerging Company Profile
Glen Clova: Fighting autoimmunity with cytokine-carrying virus-like particles
Glasgow-based company betting VLPs can beat biologics on price, dosing and safety for autoimmune and allergic diseases
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New I&I indications take center stage
Inflammation and immunology readouts to define new priority indications, modality opportunities in immune reset
BioCentury | Nov 8, 2024
Distillery Therapeutics
Sprayable nanorods delivering inflammasome inhibitors for psoriasis
BioCentury | Sep 4, 2024
Discovery & Translation
Immunoproteomics upstage genomics in I&I target discovery
Back to School 2024 identifies the target classes emerging in inflammation and immunology, and the technologies used to find them
BioCentury | Jul 8, 2024
Deals
Via $3.2B Morphic deal, Lilly gets oral integrin to compete in Entyvio’s class
Small molecule program, now in Phase II, could challenge injectable blockbuster; joins IBD drug Omvoh in pharma’s immunology arsenal
BioCentury | May 31, 2024
Product Development
Immunotherapies break into cold colorectal cancers at ASCO
Data from Regeneron, Agenus and others highlight immuno-oncology progress in genetically stable colorectal cancer
BioCentury | Apr 22, 2024
Finance
Delisting biotechs take AIM at U.K. exchange
What three companies’ decisions to delist say about life on the London exchange for development-stage biotechs
BioCentury | Apr 19, 2024
Finance
Public equity report: Depression data drive Intra-Cellular’s $500M raise
Plus public offerings for Biohaven and TScan, and PIPEs for Cullinan and Zura
BioCentury | Apr 3, 2024
Emerging Company Profile
Calluna: targeting upstream innate immune amplifiers
The Oslo-based biotech is developing a S100A4 inhibitor that it believes could be first in class in fibrotic, immunology settings
Items per page:
1 - 10 of 300